These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35285182)

  • 1. The interaction between smoking and bladder cancer genetic variants on urothelial cancer risk by disease aggressiveness.
    Teleka S; Jochems SHJ; Jirström K; Stocks T
    Cancer Med; 2022 Aug; 11(15):2896-2905. PubMed ID: 35285182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction.
    Taylor JA; Umbach DM; Stephens E; Castranio T; Paulson D; Robertson C; Mohler JL; Bell DA
    Cancer Res; 1998 Aug; 58(16):3603-10. PubMed ID: 9721868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione S-transferase (GST) M1, T1 and N-acetyltransferase 2 (NAT2) polymorphisms and urothelial cancer risk with tobacco smoking.
    Tsukino H; Nakao H; Kuroda Y; Imai H; Inatomi H; Osada Y; Katoh T
    Eur J Cancer Prev; 2004 Dec; 13(6):509-14. PubMed ID: 15548945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
    Moore LE; Baris DR; Figueroa JD; Garcia-Closas M; Karagas MR; Schwenn MR; Johnson AT; Lubin JH; Hein DW; Dagnall CL; Colt JS; Kida M; Jones MA; Schned AR; Cherala SS; Chanock SJ; Cantor KP; Silverman DT; Rothman N
    Carcinogenesis; 2011 Feb; 32(2):182-9. PubMed ID: 21037224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating interactions of polygenic risk scores and NAT2 genotypes with tobacco smoking in bladder cancer risk.
    Pradhan P; Jia G; Khankari NK; Zheng W
    Int J Cancer; 2024 Jan; 154(2):210-216. PubMed ID: 37728483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer.
    Tsukino H; Kuroda Y; Nakao H; Imai H; Inatomi H; Osada Y; Katoh T
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):99-106. PubMed ID: 14648207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure and bladder cancer risk in men by use of survival analysis and in interaction with NAT2 genotype, and by Mendelian randomization analysis.
    Teleka S; Hindy G; Drake I; Poveda A; Melander O; Liedberg F; Orho-Melander M; Stocks T
    PLoS One; 2020; 15(11):e0241711. PubMed ID: 33237904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.
    Lubin JH; Kogevinas M; Silverman D; Malats N; Garcia-Closas M; Tardón A; Hein DW; Garcia-Closas R; Serra C; Dosemeci M; Carrato A; Rothman N
    Int J Epidemiol; 2007 Feb; 36(1):236-41. PubMed ID: 17510079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk.
    Elsalem L; Al Shatnawi A; A Alfaqih M; Alshoh A; Al Demour S; Al-Daghmin A; Halalsheh O; Kheirallah K; Ahram M
    Acta Biochim Pol; 2023 Aug; 70(3):575-582. PubMed ID: 37595067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
    Cascorbi I; Roots I; Brockmöller J
    Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
    Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
    Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population.
    Cui X; Lu X; Hiura M; Omori H; Miyazaki W; Katoh T
    Environ Health Prev Med; 2013 Mar; 18(2):136-42. PubMed ID: 22961351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
    Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
    Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.
    Pesch B; Gawrych K; Rabstein S; Weiss T; Casjens S; Rihs HP; Ding H; Angerer J; Illig T; Klopp N; Bueno-de-Mesquita B; Ros MM; Kaaks R; Chang-Claude J; Roswall N; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Dossus L; Boeing H; Weikert S; Trichopoulos D; Palli D; Sieri S; Tumino R; Panico S; Quirós JR; González C; Sánchez MJ; Dorronsoro M; Navarro C; Barricarte A; Ljungberg B; Johansson M; Ulmert D; Ehrnström R; Khaw KT; Wareham N; Key TJ; Ferrari P; Romieu I; Riboli E; Brüning T; Vineis P
    Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2055-65. PubMed ID: 24092628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
    McGrath M; Michaud D; De Vivo I
    BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N -acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer.
    Hong KU; Hein DW
    Pharmacogenet Genomics; 2023 Aug; 33(6):136-137. PubMed ID: 37306342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia.
    Rouissi K; Ouerhani S; Hamrita B; Bougatef K; Marrakchi R; Cherif M; Ben Slama MR; Bouzouita M; Chebil M; Ben Ammar Elgaaied A
    Pathol Oncol Res; 2011 Dec; 17(4):879-86. PubMed ID: 21647780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.